News - Novartis

Filter

Current filters:

Novartis

Popular Filters

151 to 175 of 385 results

UK's NICE backs use of Novartis' Lucentis for diabetic macular edema

27-02-2013

Reversing an earlier negative opinion, in a final guidance issued today (February 27), the UK drugs watchdog…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

Novartis shareholders elect new board members; approve compensation system changes

25-02-2013

At the annual general meeting of Swiss drug major Novartis last Friday, as expected given earlier announcements…

ManagementNovartisPharmaceutical

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Grunenthal aims to strengthen Latin America business, appointing exec VP for the region; Novartis cancels Vasella deal

19-02-2013

German family-owned drugmaker Grunenthal Group announced the appointment of Oscar Ferenczi, former region…

GrunenthalManagementNovartisPharmaceutical

Novartis' Zortress first drug in over a decade approved by FDA to prevent organ rejection

18-02-2013

Swiss drug major Novartis (NOVN: VX) said on Friday that the US Food and Drug Administration has approved…

ImmunologicalsNorth AmericaNovartisPharmaceuticalRegulationZortress

UK's NICE says no to Novartis' Jakavi for myelofibrosis in draft guidance

13-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (February…

EuropeJakaviNovartisOncologyPharmaceuticalPricingRegulation

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

Novartis 4th-qtr sales rise 2% despite patent expiries

23-01-2013

Swiss drug major Novartis (NOVN: VX) posted fourth-quarter and full-year 2012 financial results this…

FinancialNovartisPharmaceutical

Bayer HealthCare chief Reinhardt to return to Novartis

23-01-2013

Germany's Bayer (BAYN: DE) said this morning that Jorg Reinhardt, chairman of the board of management…

BayerManagementNovartisPharmaceutical

EU approval for Novo Nordisk's Tresiba and Ryzodeg and for Novartis' for Bexsero

22-01-2013

Following positive recommendations from the European Medicines Agency's advisory committee, the European…

BexseroDiabetesEuropeNovartisNovo NordiskPharmaceuticalRegulationRyzodegTresibaVaccines

151 to 175 of 385 results

Back to top